<DOC>
	<DOC>NCT00754572</DOC>
	<brief_summary>This single arm, open-label study will assess the safety and efficacy with regar d to reduction of signs and symptoms of treatment with tocilizumab in combinatio n with methotrexate, in patients with moderate to severe active rheumatoid arthr itis. Patients will receive tocilizumab 8mg/kg iv, every 4 weeks and methotrexat e 10-25mg weekly. The anticipated time on study treatment is 3-12 months, and th e target sample size is &lt;500 individuals.</brief_summary>
	<brief_title>A Study to Assess the Effect of Tocilizumab Plus Methotrexate on Safety and Signs and Symptoms in Patients With Moderate to Severe Active Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Signs and Symptoms</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>patients &gt;=18 years with moderate to severe active RA for at least 6 months; swollen joint count &gt;=6 (66 joint count) and tender joint count &gt;=8 (68 joint count) at screening; inadequate response to stable dose of MTX; patients of reproductive potential must be using a reliable means of contraception. rheumatic autoimmune disease other than RA; patients with functional class IV RA; diagnosis of juvenile idiopathic or rheumatoid arthritis before age 16 or a history of current inflammatory joint disease other than RA; prior treatment failure with antitumor necrosis factor agent; pregnant or breastfeeding women.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>